These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital. Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328 [TBL] [Abstract][Full Text] [Related]
3. Safety of etanercept in psoriasis: a critical review. Sánchez Carazo JL; Mahiques Santos L; Oliver Martinez V Drug Saf; 2006; 29(8):675-85. PubMed ID: 16872241 [TBL] [Abstract][Full Text] [Related]
4. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. Tobin AM; Kirby B BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217 [TBL] [Abstract][Full Text] [Related]
5. Infections associated with the use of tumor necrosis factor-α inhibitors in psoriasis. Tan X; Balkrishnan R; Feldman SR J Drugs Dermatol; 2013 Mar; 12(3):e41-5. PubMed ID: 23545925 [TBL] [Abstract][Full Text] [Related]
6. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Romero-Maté A; García-Donoso C; Córdoba-Guijarro S Am J Clin Dermatol; 2007; 8(3):143-55. PubMed ID: 17492843 [TBL] [Abstract][Full Text] [Related]
10. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Viganò M; Degasperi E; Aghemo A; Lampertico P; Colombo M Expert Opin Biol Ther; 2012 Feb; 12(2):193-207. PubMed ID: 22188392 [TBL] [Abstract][Full Text] [Related]
11. Etanercept in psoriasis. Papp KA Expert Opin Pharmacother; 2004 Oct; 5(10):2139-46. PubMed ID: 15461549 [TBL] [Abstract][Full Text] [Related]
12. [Long term efficacy and safety of etanercept in psoriasis]. García-Patos Briones V; Mollet Sánchez J Actas Dermosifiliogr; 2010 May; 101 Suppl 1():12-7. PubMed ID: 20492875 [TBL] [Abstract][Full Text] [Related]
13. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M; J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482 [TBL] [Abstract][Full Text] [Related]
14. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. Kakkassery V; Mergler S; Pleyer U Curr Eye Res; 2010 Aug; 35(8):751-6. PubMed ID: 20673052 [TBL] [Abstract][Full Text] [Related]
15. Etanercept provides an effective, safe and flexible short- and long-term treatment regimen for moderate-to-severe psoriasis: a systematic review of current evidence. Strohal R; Chimenti S; Vena GA; Girolomoni G J Dermatolog Treat; 2013 Jun; 24(3):199-208. PubMed ID: 22812568 [TBL] [Abstract][Full Text] [Related]